RxDoctor Payments Data

Manjula Ananthram, MD

Advanced Heart Failure and Transplant Cardiology · Norfolk, VANPI 1164549523

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,355 of the $5,145 with a category attached, or 65.2%. UCB, Inc. accounts for 65.2% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $4,507, more than ten times the $47 reported in 2020.

$5,145in general payments, 2019–2025

Across 22 payments — averaging $233.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • Abbott$2K
  • One Lambda, Inc.$65
  • Teleflex LLC$60
  • Medtronic$47
$526,958in research payments, 2019–2025

Across 24 payments — averaging $21,957 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endotronix, Inc.$470K
  • Medtronic$32K
  • E.r. Squibb & Sons, L.L.C.$22K
  • Novartis$3K

What the payments were for

  • Consulting fees$3,35565%
  • Travel & lodging$65213%
  • Food & beverage$1,13822%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.1$3,355
Abbott16$1,618
One Lambda, Inc.2$65
Teleflex LLC1$60
Medtronic2$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,145 in reported general payments places this provider in the 55th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.

See all advanced heart failure and transplant cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$160,449
Medicare patients
802
Services billed
1,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin62$63,310
EntrestoSacubitril/Valsartan47$56,231
EliquisApixaban24$33,319
XareltoRivaroxaban27$23,560
FarxigaDapagliflozin Propanediol16$8,402
Amiodarone Hcl24$1,042
Eplerenone18$932
Candesartan Cilexetil13$902
Metoprolol Succinate65$673
Spironolactone85$647
Torsemide34$538
Atorvastatin Calcium42$384
Potassium Chloride12$263
Hydralazine Hcl26$241
Furosemide42$206

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →